Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 184

Sort by

Sort Order Select

Journal Articles

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Murielle Roussel, Valérie Lauwers-Cances, Margaret Macro, Xavier Leleu, Bruno Royer, Cyrille Hulin, Lionel Karlin, Aurore Perrot, Cyrille Touzeau, Marie-Lorraine Chrétien, Sophie Rigaudeau, Mamoun Dib, Emmanuelle Nicolas-Virelizier, Martine Escoffre-Barbe, Karim Belhadj, Clara Mariette, Anne-Marie Stoppa, Carla Araujo, Chantal Doyen, Jean Fontan, Brigitte Kolb, Laurent Garderet, Sabine Brechignac, Jean-Valère Malfuson, Arnaud Jaccard, Pascal Lenain, Cécile Borel, Benjamin Hebraud, Omar Benbrahim, Véronique Dorvaux, Salomon Manier, Karine Augeul-Meunier, Marie-Christiane Vekemans, Edouard Randriamalala, Driss Chaoui, Jo Caers, Carine Chaleteix, Lofti Benboubker, Laure Vincent, Sylvie Glaisner, Patricia Zunic, Borhane Slama, Jean-Richard Eveillard, Catherine Humbrecht-Kraut, Véronique Morel, Philippe Mineur, Jean-Claude Eisenmann, Hélène Demarquette, Valentine Richez, Marguerite Vignon, Denis Caillot, Thierry Facon, Philippe Moreau, Anne-Laurène Colin, Pascale Olivier, Soraya Wuilleme, Hervé Avet-Loiseau, Jill Corre, Michel Attal

Blood (2022) 139 (18): 2747–2757.

https://doi.org/10.1182/blood.2021014635

Published: 2022

Includes: Supplemental data

Journal Articles

Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients

Blood (2021) 138 (Supplement 1): 2753.

https://doi.org/10.1182/blood-2021-152136

Published: 2021

Journal Articles

Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM)

Aurore Perrot, Valérie Lauwers-Cances, Cyrille Touzeau, Olivier Decaux, Cyrille Hulin, Magaret Macro, Anne-Marie Stoppa, Marie Lorraine Chretien, Lionel Karlin, Clara Mariette, Caroline Jacquet, Murielle Roussel, Coralie Guillemot, Laure Devlamynck, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal

Blood (2021) 138 (Supplement 1): 464.

https://doi.org/10.1182/blood-2021-146040

Published: 2021

Journal Articles

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier, Laurent Garderet, Martine Escoffre-Barbe, Clara Mariette, Lotfi Benboubker, Denis Caillot, Cécile Sonntag, Cyrille Touzeau, Jehan Dupuis, Philippe Moreau, Xavier Leleu, Thierry Facon, Benjamin Hébraud, Jill Corre, Michel Attal

Blood (2021) 138 (2): 113–121.

https://doi.org/10.1182/blood.2021010744

Published: 2021

Journal Articles

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-134538

Published: 2020

Journal Articles

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Ola Landgren, MD PhD, Michel Attal, MD PhD, Dickran Kazandjian, MD, Murielle Roussel, MD, Jagoda K. Jasielec, MD, Dominik Dytfeld, Aparna Anderson, Tara Kervin, Karim Iskander, Khalid Mezzi, Tim Welliver, Akeem Yusuf, PhD BPharm, Andrzej Jakubowiak, MD PhD

Blood (2019) 134 (Supplement_1): 1891.

https://doi.org/10.1182/blood-2019-127076

Published: 2019

Journal Articles

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

Fredrik H. Schjesvold, MD PhD, Paul G. Richardson, MD, Michel Attal, MD PhD, Thierry Facon, MD, Adrián Alegre, MD, Andrew Spencer, DM, Artur Jurczyszyn, MD, Kazutaka Sunami, MD PhD, Laurent Frenzel, MD PhD, Chang-Ki Min, MD PhD, Solenn Le-Guennec, Frank Campana, MD, Helgi van de Velde, MD PhD, Samira Bensfia, MD, Sara Bringhen

Blood (2019) 134 (Supplement_1): 1893.

https://doi.org/10.1182/blood-2019-128010

Published: 2019

Journal Articles

Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

Anil Aktas Samur, PhD, Mariateresa Fulciniti, PhD, Raphael Szalat, Jill Corre, PharmD, PhD, Niccolo Bolli, MD PhD, Philippe Moreau, MD, Michel Attal, MD PhD, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Hervé Avet-Loiseau, MD PhD, Mehmet Kemal Samur, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 3089.

https://doi.org/10.1182/blood-2019-128570

Published: 2019

Journal Articles

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Mehmet Kemal Samur, PhD, Anil Aktas Samur, PhD, Tessa Han, Marco Roncador, MD MSc, Mariateresa Fulciniti, PhD, Raphael Szalat, Masood A. Shammas, PhD, Jill Corre, PharmD, PhD, Paul G. Richardson, MD, Florence Magrangeas, Stephane Minvielle, PhD, Philippe Moreau, MD, Michel Attal, MD PhD, Anjan Thakurta, Kenneth C. Anderson, MD, Giovanni Parmigiani, PhD, Herve Avet-Loiseau, MD PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 3055.

https://doi.org/10.1182/blood-2019-128521

Published: 2019

Journal Articles

Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma

Tessa Han, Stephane Minvielle, PhD, Anil Aktas Samur, PhD, Mariateresa Fulciniti, PhD, Florence Magrangeas, PhD, Paul G. Richardson, MD, Philippe Moreau, MD, Michel Attal, MD PhD, Kenneth C. Anderson, MD, Hervé Avet-Loiseau, MD PhD, Giovanni Parmigiani, PhD, Mehmet Kemal Samur, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4348.

https://doi.org/10.1182/blood-2019-130343

Published: 2019

Journal Articles

The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies

Paul G. Richardson, MD, Joseph Mikhael, MD FRCPC, MD, Thierry Facon, MD, William I. Bensinger, Sandrine Macé, Marielle Chiron, Helgi van de Velde, MD PhD, Frank Campana, MD, Li Liu, Michel Attal, MD PhD

Blood (2019) 134 (Supplement_1): 3179.

https://doi.org/10.1182/blood-2019-128071

Published: 2019

Journal Articles

Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Cyrille Hulin, MD, Paul G. Richardson, MD, Michel Attal, MD PhD, Hugh J. Goodman, FRACP, Vadim A Doronin, MD, Ivan Spicka, MD PhD Prof, Solenn Le-Guennec, Frank Campana, MD, Helgi van de Velde, MD PhD, Meral Beksac, MD

Blood (2019) 134 (Supplement_1): 3185.

https://doi.org/10.1182/blood-2019-129840

Published: 2019

Journal Articles

Maintenance with Weekly Carfilzomib in Elderly Newly Diagnosed Multiple Myeloma (IFM 2012-03)

Arthur Bobin, Guillemette Fouquet, Alain Duhamel, PU/PH, Salomon Manier, MD PhD, Lionel Karlin, MD, Brigitte Kolb, MD, Mourad Tiab, MD, Carla Araujo, MD, Nathalie Meuleman, PhD MD, Jean Valère Malfuson, MD, Pascal Bourquard, MD, Pascal Lenain, MD, Arnaud Jaccard, MD PhD, Karim Belhadj, MD, Michel Attal, MD PhD, Philippe Moreau, MD, Cyrille Hulin, MD, Xavier Leleu, MD PhD

Blood (2019) 134 (Supplement_1): 3190.

https://doi.org/10.1182/blood-2019-131793

Published: 2019

Journal Articles

Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)

Murielle Roussel, MD, Benjamin Hebraud, MD, Cyrille Hulin, MD, Xavier Leleu, MD PhD, Thierry Facon, MD, Eileen Boyle, MD PhD, Cyrille Touzeau, MD PhD, Brigitte Pegourie, MD, Aurore Perrot, MD PhD, Anne-Marie Stoppa, MD, Jean-Pierre Marolleau, MD PhD, Philippe Moreau, MD, Herve Avet-Loiseau, MD PhD, Laure Devlamynck, Valerie Lauwers-Cances, MD, Michel Attal, MD PhD

Blood (2019) 134 (Supplement_1): 3159.

https://doi.org/10.1182/blood-2019-123184

Published: 2019

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab Plus Pomalidomide and Dexamethasone: Icaria-MM Study

Katherine Houghton, MSc, BSc, Meletios A. Dimopoulos, MD, Peggy Lin, PhD, Sophie Guillonneau, MSc, Denise Bury, MPH, PhD, Michel Attal, MD PhD, Paul G. Richardson, MD, Michel Delforge, MD PhD

Blood (2019) 134 (Supplement_1): 1850.

https://doi.org/10.1182/blood-2019-128220

Published: 2019

Journal Articles

Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14)

Alice Cleynen, Mehmet Samur, Aurore Perrot, Laure Buisson, Sabrina Maheo, Mariateresa Fulciniti, Michel Attal, Nikhil Munshi, Hervé Avet-Loiseau, Jill Corre

Blood (2018) 132 (26): 2778–2780.

https://doi.org/10.1182/blood-2018-09-876433

Published: 2018

Journal Articles

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Blood (2018) 132 (24): 2555–2563.

https://doi.org/10.1182/blood-2018-07-863829

Published: 2018

Includes: Supplemental data

Journal Articles

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Blood (2018) 132 (23): 2456–2464.

https://doi.org/10.1182/blood-2018-06-858613

Published: 2018

Includes: Supplemental data

Journal Articles

Deciphering the Chronology of Copy Number Alterations in Multiple Myeloma (MM): What Comes First?

Anil Aktas Samur, PhD, Mehmet Kemal Samur, PhD, Stephane Minvielle, PhD, Florence Magrangeas, PhD, Masood A. Shammas, PhD, Mariateresa Fulciniti, PhD, Michel Attal, MD PhD, Philippe Moreau, Kenneth Anderson, MD, Giovanni Parmigiani, Hervé Avet-Loiseau, MD PhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 3171.

https://doi.org/10.1182/blood-2018-99-120101

Published: 2018

Journal Articles

Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials

Blood (2018) 132 (Supplement 1): 257.

https://doi.org/10.1182/blood-2018-99-111321

Published: 2018

NARROW

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study

The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma

Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma

The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies

Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Maintenance with Weekly Carfilzomib in Elderly Newly Diagnosed Multiple Myeloma (IFM 2012-03)

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab Plus Pomalidomide and Dexamethasone: Icaria-MM Study

Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14)

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Deciphering the Chronology of Copy Number Alterations in Multiple Myeloma (MM): What Comes First?

Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only